Revealed: A Potential Huge Investing Opportunity for Investors
Here is the latest financial fact sheet of SYNCOM FORMULATIONS. For more details, see the SYNCOM FORMULATIONS quarterly results and SYNCOM FORMULATIONS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -2.8 |
No. of shares | m | 940.00 |
1 Week | % | -1.6 |
1 Month | % | 10.2 |
1 Year | % | 121.9 |
52 week H/L | Rs | 18.7/6.1 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
SYNCOM FORMULATIONS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 2 | 1 | 4 | 19 | 13 | |
Low | Rs | 1 | NA | 1 | 3 | 5 | |
Sales per share (Unadj.) | Rs | 2.4 | 2.6 | 3.1 | 2.5 | 2.4 | |
Earnings per share (Unadj.) | Rs | 0.1 | 0.2 | 0.4 | 0.2 | 0.2 | |
Diluted earnings per share | Rs | 0.1 | 0.2 | 0.3 | 0.2 | 0.2 | |
Cash flow per share (Unadj.) | Rs | 0.2 | 0.2 | 0.4 | 0.3 | 0.3 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 1.7 | 1.9 | 2.3 | 2.5 | 2.7 | |
Adj. book value per share | Rs | 1.4 | 1.5 | 1.9 | 2.3 | 2.7 | |
Shares outstanding (eoy) | m | 780.65 | 780.65 | 789.95 | 862.45 | 940.00 | |
Price / Sales ratio | x | 0.5 | 0.3 | 0.7 | 4.4 | 3.7 | |
Avg P/E ratio | x | 7.9 | 4.4 | 6.3 | 49.1 | 41.1 | |
P/CF ratio (eoy) | x | 5.8 | 3.4 | 5.5 | 40.9 | 33.5 | |
Price / Book Value ratio | x | 0.7 | 0.4 | 1.0 | 4.5 | 3.2 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 874 | 625 | 1,833 | 9,716 | 8,249 | |
Total wages/salary | Rs m | 152 | 158 | 182 | 207 | 244 |
SYNCOM FORMULATIONS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 1,868 | 2,055 | 2,448 | 2,197 | 2,243 | |
Other income | Rs m | 51 | 52 | 71 | 120 | 146 | |
Total revenues | Rs m | 1,919 | 2,107 | 2,519 | 2,317 | 2,389 | |
Gross profit | Rs m | 118 | 167 | 381 | 201 | 199 | |
Depreciation | Rs m | 40 | 41 | 40 | 39 | 45 | |
Interest | Rs m | 2 | 6 | 5 | 19 | 34 | |
Profit before tax | Rs m | 127 | 173 | 407 | 262 | 266 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 16 | 30 | 115 | 64 | 65 | |
Profit after tax | Rs m | 111 | 143 | 292 | 198 | 201 | |
Gross profit margin | % | 6.3 | 8.1 | 15.6 | 9.1 | 8.9 | |
Effective tax rate | % | 12.5 | 17.6 | 28.3 | 24.4 | 24.5 | |
Net profit margin | % | 5.9 | 6.9 | 11.9 | 9.0 | 8.9 |
SYNCOM FORMULATIONS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 813 | 894 | 1,898 | 1,398 | 1,817 | |
Current liabilities | Rs m | 358 | 312 | 967 | 783 | 1,132 | |
Net working cap to sales | % | 24.4 | 28.3 | 38.0 | 28.0 | 30.6 | |
Current ratio | x | 2.3 | 2.9 | 2.0 | 1.8 | 1.6 | |
Inventory Days | Days | 91 | 86 | 30 | 183 | 231 | |
Debtors Days | Days | 80,767,198 | 76,978,436 | 1,116 | 1,122 | 1,229 | |
Net fixed assets | Rs m | 947 | 945 | 1,018 | 1,684 | 1,961 | |
Share capital | Rs m | 781 | 781 | 790 | 862 | 940 | |
"Free" reserves | Rs m | 546 | 676 | 988 | 1,309 | 1,620 | |
Net worth | Rs m | 1,326 | 1,457 | 1,778 | 2,172 | 2,560 | |
Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
Total assets | Rs m | 1,760 | 1,839 | 2,917 | 3,082 | 3,778 | |
Interest coverage | x | 52.5 | 29.2 | 86.3 | 14.6 | 8.8 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 1.1 | 1.1 | 0.8 | 0.7 | 0.6 | |
Return on assets | % | 6.4 | 8.1 | 10.2 | 7.0 | 6.2 | |
Return on equity | % | 8.4 | 9.8 | 16.4 | 9.1 | 7.8 | |
Return on capital | % | 9.7 | 12.3 | 23.2 | 12.9 | 11.7 | |
Exports to sales | % | 60.4 | 59.8 | 69.7 | 65.9 | 63.3 | |
Imports to sales | % | 0.1 | 0.6 | 0.2 | 1.8 | 7.7 | |
Exports (fob) | Rs m | 1,127 | 1,229 | 1,707 | 1,447 | 1,419 | |
Imports (cif) | Rs m | 2 | 12 | 4 | 39 | 172 | |
Fx inflow | Rs m | 1,127 | 1,229 | 1,707 | 1,447 | 1,419 | |
Fx outflow | Rs m | 3 | 14 | 4 | 56 | 204 | |
Net fx | Rs m | 1,124 | 1,215 | 1,704 | 1,391 | 1,215 |
SYNCOM FORMULATIONS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 43 | 59 | -21 | 163 | 105 | |
From Investments | Rs m | 24 | 15 | -754 | -271 | -450 | |
From Financial Activity | Rs m | -2 | -65 | 720 | 83 | 350 | |
Net Cashflow | Rs m | 66 | 9 | -55 | -25 | 6 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Kedarmal Bankda | COMP SEC: Prachi Jain | YEAR OF INC: 1988 | BSE CODE: 524470 | FV (Rs): 1 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare SYNCOM FORMULATIONS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Indian share markets are trading higher with the Sensex up by 377 points and Nifty is trading 60 points higher.